These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35464413)

  • 1. Skin Interstitial Fluid and Plasma Multiplex Cytokine Analysis Reveals IFN-γ Signatures and Granzyme B as Useful Biomarker for Activity, Severity and Prognosis Assessment in Vitiligo.
    Ng CY; Chiu YC; Chan YP; Lin YJ; Chung PH; Chung WH; Ku CL
    Front Immunol; 2022; 13():872458. PubMed ID: 35464413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the elevated IFN-γ in vitiligo patients by human anti- IFN-γ monoclonal antibody hampers direct cytotoxicity in melanocyte.
    Ng CY; Chan YP; Chiu YC; Shih HP; Lin YN; Chung PH; Huang JY; Chen HK; Chung WH; Ku CL
    J Dermatol Sci; 2023 Jun; 110(3):78-88. PubMed ID: 37221109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.
    Strassner JP; Rashighi M; Ahmed Refat M; Richmond JM; Harris JE
    J Am Acad Dermatol; 2017 May; 76(5):847-855.e5. PubMed ID: 28259440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum cytokine profiles predict response to systemic glucocorticoid in active vitiligo.
    Wang X; Fan J; He K; Chen J; Li S
    Postepy Dermatol Alergol; 2024 Apr; 41(2):189-196. PubMed ID: 38784928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cross-Sectional Study of the Levels of Cytokines IL-6, TNF-α, and IFN-γ in Blood and Skin (Lesional and Uninvolved) of Vitiligo Patients and their Possible Role as Biomarkers.
    De A; Choudhary N; Sil A; Sarda A; Hasanoor Raja AH
    Indian J Dermatol; 2023; 68(1):67-72. PubMed ID: 37151272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease.
    Richmond JM; Bangari DS; Essien KI; Currimbhoy SD; Groom JR; Pandya AG; Youd ME; Luster AD; Harris JE
    J Invest Dermatol; 2017 Feb; 137(2):350-358. PubMed ID: 27686391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitiligo: Correlation with Cytokine Profiles and its Role in Novel Therapeutic Strategies: A Case-Control Study.
    Desai K; Kumar HK; Naveen S; Somanna P
    Indian Dermatol Online J; 2023; 14(3):361-365. PubMed ID: 37266084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation.
    Lin F; Hu W; Xu W; Zhou M; Xu AE
    Sci Rep; 2021 Sep; 11(1):18298. PubMed ID: 34521889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines.
    Grimes PE; Morris R; Avaniss-Aghajani E; Soriano T; Meraz M; Metzger A
    J Am Acad Dermatol; 2004 Jul; 51(1):52-61. PubMed ID: 15243524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity.
    Bozza FA; Cruz OG; Zagne SM; Azeredo EL; Nogueira RM; Assis EF; Bozza PT; Kubelka CF
    BMC Infect Dis; 2008 Jun; 8():86. PubMed ID: 18578883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.
    Rashighi M; Agarwal P; Richmond JM; Harris TH; Dresser K; Su MW; Zhou Y; Deng A; Hunter CA; Luster AD; Harris JE
    Sci Transl Med; 2014 Feb; 6(223):223ra23. PubMed ID: 24523323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome.
    El-Domyati M; El-Din WH; Rezk AF; Chervoneva I; Lee JB; Farber M; Uitto J; Igoucheva O; Alexeev V
    Arch Dermatol Res; 2022 Apr; 314(3):275-284. PubMed ID: 33866437
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Wu M; Wang L; Wu H; Yang M; He Z; Chen Y; Zhang H
    Front Immunol; 2023; 14():1158883. PubMed ID: 37207234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo.
    Chang Y; Kang P; Cui T; Guo W; Zhang W; Du P; Yi X; Guo S; Gao T; Li C; Li S
    J Transl Med; 2023 Jul; 21(1):434. PubMed ID: 37403086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in extracellular cytokines in predicting disease severity and final clinical outcome of patients with blunt chest trauma.
    Kumari M; Mathur P; Aggarwal R; Madan K; Sagar S; Gupta A; Khurana S; Sreenivas V; Kumar S
    Immunobiology; 2021 May; 226(3):152087. PubMed ID: 33857690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin.
    Szegedi K; Lutter R; Res PC; Bos JD; Luiten RM; Kezic S; Middelkamp-Hup MA
    J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2136-44. PubMed ID: 25980674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: A multicenter cross-sectional study.
    Abdallah M; El-Mofty M; Anbar T; Rasheed H; Esmat S; Al-Tawdy A; Fawzy MM; Abdel-Halim D; Hegazy R; Gawdat H; Bassiouny D; Ibrahim MA; Sany I; El-Bassiouny M; Khalil M; Abdel-Aziz A; El Maadawi ZM; Mostafa WZ;
    Pigment Cell Melanoma Res; 2018 Mar; 31(2):330-336. PubMed ID: 29094481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Serum Levels of IFN-
    Tomaszewska K; Kozłowska M; Kaszuba A; Lesiak A; Narbutt J; Zalewska-Janowska A
    Oxid Med Cell Longev; 2020; 2020():5693572. PubMed ID: 32832001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of disease activity in vitiligo: A systematic review.
    Speeckaert R; Speeckaert M; De Schepper S; van Geel N
    Autoimmun Rev; 2017 Sep; 16(9):937-945. PubMed ID: 28698094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased systemic and epidermal levels of IL-17A and IL-1β promotes progression of non-segmental vitiligo.
    Bhardwaj S; Rani S; Srivastava N; Kumar R; Parsad D
    Cytokine; 2017 Mar; 91():153-161. PubMed ID: 28082234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.